TY - JOUR T1 - Senotherapeutic peptide reduces skin biological age and improves skin health markers JF - bioRxiv DO - 10.1101/2020.10.30.362822 SP - 2020.10.30.362822 AU - Alessandra Zonari AU - Lear E. Brace AU - Kallie Z. Al-Katib AU - William F. Porto AU - Daniel Foyt AU - Mylieneth Guiang AU - Edgar Andres Ochoa Cruz AU - Bailey Marshall AU - Willian G. Salgueiro AU - Mehmet Dinçer Inan AU - Mizanur Rahman AU - Taslim Anupom AU - Siva Vanapalli AU - Marcelo A. Mori AU - Octavio L. Franco AU - Carolina R. Oliveira AU - Mariana Boroni AU - Juliana L. Carvalho Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/11/03/2020.10.30.362822.abstract N2 - Skin aging has been primarily related to aesthetics and beauty. Therefore, interventions have focused on reestablishing skin appearance, but not necessarily skin health, function, and resilience. Recently, cellular senescence was shown to play a role in age-related skin function deterioration and influence organismal health and, potentially, longevity. In the present study, a two-step screening was performed to identify peptides capable of reducing cellular senescence in human dermal fibroblasts (HDF) from Hutchinson-Gilford Progeria (HGPS) patients. From the top four peptides of the first round of screening, we built a 764-peptide library using amino acid scanning, of which the second screen led to the identification of peptide 14. Peptide 14 effectively decreased HDF senescence induced by HGPS, chronological aging, ultraviolet-B radiation, and etoposide treatment, without inducing significant cell death, and likely by modulating longevity and senescence pathways. We further validated the effectiveness of peptide 14 using human skin equivalents and skin biopsies, where peptide 14 promoted skin health and reduced senescent cell markers, as well as the biological age of samples, according to the Skin-Specific DNA methylation clock, MolClock. Topical application of peptide 14 outperformed Retinol treatment, the current gold-standard in “anti-aging” skin care. Finally, we determined that peptide 14 is safe for long-term applications and also significantly extends both the lifespan and healthspan of C. elegans worms tested in two independent testings. This highlights the potential for geroprotective applications of the senotherapeutic compounds identified using our screening platform beyond the skin.Competing Interest StatementMB, AZ, CR, LB, EA, and JC are named as inventors of a patent directed at this invention, which is solely owned by OneSkin, Inc. MB, AZ, CR, EA, and JC are co-founders of OneSkin Inc. SAV and MR are co-founders of the startup company NemaLife Inc. that is commercializing microfluidic devices used in this study and licensed from Texas Tech University. SAV, MR, and TA are named inventors on a patent owned by Texas Tech University and receive royalty fees. ER -